Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 5/20 | 0.41 |
| ▸ | CA1 | P00915 | 3/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | AKT1 | P31749 | 1/20 | 0.35 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
| ▸ | CTSB | P07858 | 1/20 | 0.34 |
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25495976 | 0.82 | FOLH1 (0.38) | CA2CA1FOLH1 | |
| SCHEMBL23080720 | 0.81 | CA2 (0.43) | CA2CA1NAMPTSIGMAR1PTGER4 | |
| SCHEMBL26088797 | 0.76 | CA2 (0.49) | CA2CA1NAMPTSIGMAR1MAPT | |
| SCHEMBL28848653 | 0.75 | CA2 (0.56) | CA2CA1NAMPTSIGMAR1MAPT | |
| SCHEMBL23538085 | 0.75 | CA2 (0.40) | CA2CA1NAMPTSIGMAR1PTGER4 | |
| SCHEMBL25495978 | 0.74 | CA2 (0.46) | CA2CA1NAMPTMAPTTDP1 | |
| SCHEMBL13527791 | 0.73 | HDAC1 (0.43) | NAMPTAKT1CTSLCTSBCTSS | |
| SCHEMBL13527841 | 0.72 | ADRB2 (0.42) | NAMPTAKT1FOLH1 | |
| SCHEMBL19876836 | 0.71 | CA2 (0.49) | CA2CA1NAMPTMAPTTDP1 | |
| SCHEMBL8251339 | 0.71 | HDAC3 (0.52) | MAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159592-A1 | PCSK9 ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME LLC | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159592-A1 | PCSK9 ANTAGONIST COMPOUNDS | PCSK9, PCSK7, PCSK6 | CA2 4141/4885CA1 4496/4885NAMPT 2275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.